HC Wainwright Analysts Lower Earnings Estimates for BOLT

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Equities researchers at HC Wainwright lowered their Q2 2026 EPS estimates for Bolt Biotherapeutics in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($2.97) for the quarter, down from their previous estimate of ($2.79). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($11.10) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q3 2026 earnings at ($2.40) EPS, Q4 2026 earnings at ($2.01) EPS and FY2026 earnings at ($11.10) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million.

Several other brokerages have also recently commented on BOLT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a report on Thursday. They set a “buy” rating and a $22.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $34.67.

Bolt Biotherapeutics Price Performance

Shares of BOLT opened at $5.25 on Monday. Bolt Biotherapeutics has a 12 month low of $3.91 and a 12 month high of $7.35. The firm’s 50 day moving average is $4.74 and its 200-day moving average is $5.09. The stock has a market capitalization of $10.08 million, a PE ratio of -0.32 and a beta of 1.12. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.98.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares during the last quarter. Susquehanna International Group LLP bought a new position in Bolt Biotherapeutics in the third quarter valued at approximately $89,000. Shay Capital LLC bought a new position in Bolt Biotherapeutics in the third quarter valued at approximately $85,000. Squarepoint Ops LLC increased its stake in Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares during the last quarter. Finally, T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth $208,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.